|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases
|
1R01CA227479-01
|
$351,726
|
SIMONE, NICOLE
|
THOMAS JEFFERSON UNIVERSITY
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
5R21CA208736-02
|
$180,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
5R01CA216248-02
|
$607,904
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Epigenetic effects of the premalignant field
|
5R01CA208620-03
|
$415,599
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-03
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
|
1R01CA216101-01A1
|
$670,933
|
SHADEL, GERALD
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
5R01CA205632-03
|
$457,974
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
5R01CA208735-02
|
$730,063
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In Situ
|
5R01CA194697-04
|
$347,700
|
ZHANG, SIYUAN
|
UNIVERSITY OF NOTRE DAME
|
|
1/2 Langston University- UNTHSC Partnership for Cancer Research and Education
|
1P20CA233391-01
|
$210,731
|
QUINN, BYRON
|
LANGSTON UNIVERSITY
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-09
|
$1,304,869
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
|
5R01CA201250-03
|
$695,342
|
LARSON, STEVEN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
15-PGDH in Cholangiocarcinogenesis
|
5R01CA102325-12
|
$344,269
|
WU, TONG
|
TULANE UNIVERSITY OF LOUISIANA
|
|
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
|
1P20CA233355-01
|
$255,958
|
VISHWANATHA, JAMBOOR
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-09
|
$1,003,901
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-13
|
$1,101,004
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118948-13
|
$1,170,535
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis
|
5R01CA195443-03
|
$208,861
|
KAMAYA, AYA
|
STANFORD UNIVERSITY
|
|
A 3D Model of the Perivascular Niche to Investigate Glioblastoma Invasion
|
1F31CA228317-01
|
$39,703
|
WOLF, KAYLA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
5R01CA218356-02
|
$601,750
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC
|
1R21CA229927-01
|
$218,588
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-10
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A mechanistic dissection of the role of Eya3 in breast cancer metastasis
|
1F99CA234940-01
|
$36,490
|
ZHOU, HENGBO
|
UNIVERSITY OF COLORADO DENVER
|
|
A Microfluidics Approach to Investigate Tumor Cell Trafficking in Bone Marrow
|
5F32CA210540-02
|
$61,174
|
GLASER, DREW
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$154,883
|
Kelly Siebenlist, Kathleen
|
CCR (NCI)
|
|
A multi-fluorescent intravital microscopy approach to study osteosarcoma
|
7R21CA208618-02
|
$176,380
|
INTINI, GIUSEPPE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
A multiplexed approach to improve tumoral targeting and chemotherapeutic treatment
|
1R01CA222802-01A1
|
$412,139
|
LAW, BENEDICT
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A nanosystem for tumor treatment and imaging
|
5R01CA188883-05
|
$404,625
|
RUOSLAHTI, ERKKI
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
5R01CA196631-03
|
$395,911
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
|
A new imaging approach to radiotherapy planning for lung cancer
|
5R01CA193050-04
|
$577,910
|
RIZI, RAHIM
|
UNIVERSITY OF PENNSYLVANIA
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A New Small-Molecule Kinase Inhibitor for Breast Cancer
|
1R41CA235943-01
|
$300,000
|
HOLTZMAN, MICHAEL
|
NUPEAK THERAPEUTICS, INC.
|
|
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use
|
7R01CA207645-03
|
$575,548
|
OSBORNE, JOSEPH
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A novel approach in Basal Cell Carcinoma treatment; targeting CRD-BP
|
1R03CA223099-01A1
|
$68,371
|
NOUBISSI, FELICITE
|
JACKSON STATE UNIVERSITY
|
|
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
|
5R01CA200919-03
|
$383,156
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
5R01CA204926-02
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel lineage pathway controls metabolic adaptation by metastatic lung cancers
|
5R01CA191489-04
|
$380,278
|
NGUYEN, DON
|
YALE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|